Open AccessMetastatic cervical cancer: clinical experience with pembrolizumab application. Case report
Author(s) -
Anna E. Protasova,
Anna E. Protasova,
Liubov V. Strakh,
Страх Любовь Владимировна,
Elena I. Lando,
Ландо Елена Игоревна,
Elena V. Sidorkina,
Сидоркина Елена Викторовна
Publication year - 2021
Publication title -
sovremennaâ onkologiâ
Language(s) - English
Resource type - Journals
eISSN - 1815-1442
pISSN - 1815-1434
DOI - 10.26442/18151434.2021.2.201009
Subject(s) - medicine , pembrolizumab , carboplatin , bevacizumab , oncology , cervical cancer , regimen , lung cancer , chemotherapy , cancer , paclitaxel , cisplatin , immunotherapy
Cervical cancer (CC) ranks fourth for cancer incidences in women after breast cancer, colorectal cancer and lung cancer. There is a steady increase in the incidence of invasive forms of CC in Russia. Over the past quarter of a century, the mortality rate of reproductive age group women with cervical cancer has increased by 2 times. The standard treatment options for cervical cancer progression were the regime of paclitaxel plus cisplatin (carboplatin). The addition of an antiangiogenic therapy (bevacizumab) to the standard chemotherapy regimen increases overall survival of only 4%. The response to other lines of chemotherapy does not exceed 10% after the therapy using the combination of paclitaxel + carboplatin + bevacizumab. The results of KEYNOTE-158 trial demonstrated objective responses in 91% of CC patients lasting for more than 6 months in case of application of pembrolizumab 200 mg every 3 weeks in cases of PD-L1 expression (CPS1) with acceptable toxicity. The presented clinical case of successful treatment using pembrolizumab in women with PD-L1 expression in metastatic CC has a beneficial effect on further accumulation of experience and could help to choose the right treatment options in order to increase the efficacy of the therapy and to increase the survival rates for this category of patients.